Literature DB >> 21666249

Clinical outcome of renal tubular damage in chronic heart failure.

Kevin Damman1, Serge Masson, Hans L Hillege, Aldo P Maggioni, Adriaan A Voors, Cristina Opasich, Dirk J van Veldhuisen, Laura Montagna, Franco Cosmi, Gianni Tognoni, Luigi Tavazzi, Roberto Latini.   

Abstract

AIMS: Both reduced glomerular filtration and increased urinary albumin excretion independently determine outcome in patients with chronic heart failure (HF). However, tubulo-interstitial injury might indicate renal damage, even in the presence of normal glomerular filtration. We studied the relationship between tubular damage, glomerular filtration, urinary albumin excretion, and outcome in HF patients. METHODS AND
RESULTS: In 2130 patients participating in the GISSI-HF trial, we measured urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and three urinary markers of tubular damage: N-acetyl-beta-D-glucosaminidase (NAG), kidney injury molecule 1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL). We assessed the relationship between the individual tubular damage markers and the combined endpoint of all-cause mortality and HF hospitalizations. Mean age was 67 ± 11 years, and 21% were female. Urinary NAG 13.7 (7.8-22) U/gCr, KIM-1 1939 (671-3871) ng/gCr, and NGAL 36 (14-94) µg/gCr were markedly elevated above normal levels. All individual tubular markers were independently associated with the combined endpoint: NAG: adjusted hazard ratio (HR) 1.22; 95% confidence interval (CI), 1.10-1.36; P< 0.001, KIM-1 HR 1.13; 95% CI, 1.02-1.24; P= 0.018 and NGAL HR 1.10; 95% CI, 1.00-1.20; P= 0.042; all per log standard deviation increase). Even in patients with a normal eGFR, increased tubular markers were related to a poorer outcome. The combination of impaired eGFR, increased UACR, and high NAG was associated with a HR of 3.00; 95% CI, 2.29-3.95; P< 0.001, compared with those without these abnormalities.
CONCLUSION: Tubular damage is related to a poor clinical outcome in HF patients even when eGFR is normal.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666249     DOI: 10.1093/eurheartj/ehr190

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  64 in total

1.  Management of the cardiorenal syndrome in acute heart failure.

Authors:  Valentina Lazzarini; G Michael Felker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 2.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

Review 3.  Cardiac biomarkers: new tools for heart failure management.

Authors:  Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

4.  Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure.

Authors:  Frederik H Verbrugge; Matthias Dupont; Zhili Shao; Kevin Shrestha; Dhssraj Singh; Michael Finucan; Wilfried Mullens; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09       Impact factor: 5.712

5.  N-Acetyl-β-D-Glucosaminidase Does Not Enhance Prediction of Cardiovascular or All-Cause Mortality by Albuminuria in a Low-Risk Population.

Authors:  Marit D Solbu; Ingrid Toft; Maja-Lisa Løchen; Ellisiv B Mathiesen; Bjørn O Eriksen; Toralf Melsom; Inger Njølstad; Tom Wilsgaard; Trond G Jenssen
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

Review 6.  The kidney in heart failure: an update.

Authors:  Kevin Damman; Jeffrey M Testani
Journal:  Eur Heart J       Date:  2015-04-02       Impact factor: 29.983

Review 7.  Management of the cardiorenal syndrome in decompensated heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Cardiorenal Med       Date:  2014-12       Impact factor: 2.041

Review 8.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 9.  The role of the kidney in acute and chronic heart failure.

Authors:  Gaetano Ruocco; Alberto Palazzuoli; Jozine M Ter Maaten
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

10.  Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease.

Authors:  Yalcin Solak; Mahmut Ilker Yilmaz; Dimitrie Siriopol; Mutlu Saglam; Hilmi Umut Unal; Halil Yaman; Mahmut Gok; Hakki Cetinkaya; Abduzhappar Gaipov; Tayfun Eyileten; Sebahattin Sari; Ali Osman Yildirim; Halil Zeki Tonbul; Suleyman Turk; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-10-26       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.